Abstract
In a retrospective review of 24 patients with histoplasmosis, blastomycosis, or coccidioidomycosis treated with voriconazole (most for salvage therapy), the outcome was favorable (improved or stable) for 22 (95.8%) within 2 months of starting voriconazole and for 20 (83.3%) at the last follow-up. Prospective studies are required to determine its role in the treatment of endemic mycoses.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antifungal Agents / therapeutic use*
-
Blastomycosis / drug therapy*
-
Coccidioidomycosis / drug therapy*
-
Female
-
Histoplasmosis / drug therapy*
-
Humans
-
Male
-
Middle Aged
-
Pyrimidines / therapeutic use*
-
Retrospective Studies
-
Triazoles / therapeutic use*
-
Voriconazole
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
Voriconazole